Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin with Radiotherapy for Locally Advanced HER2+ Solid Tumors
NCT05940896Phase 1Recruiting
- Sponsor
- RemeGen
- Start
- Jun 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disitamab vedotin in solid tumor, sponsored by RemeGen. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 90 days. Started Jun 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05940896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940896.